GRDX:NASDAQ, GridAI Technologies Corp Com (New) 2025

Why GRDX stock fell on November 13

GridAI Technologies Corp Com (New) 2025 fell 31.0% on Friday, November 13, 2026, on 503,600 shares, 4.2 times its average daily volume. The headline around the move:

GRDX stock overview

GridAI Technologies Corp Com (New) 2025 (GRDX:NASDAQ) closed at $3.30 on November 17, 2026, unchanged on the day. The stock trades 52.4% below its 52-week high of $6.93 and 76.5% above its 52-week low of $1.87. Over the past year, it gained 7.1%. GridAI Technologies Corp Com (New) 2025 is part of the Health Care sector.

Key figures

Price
$3.30
Day change
0.00%
Volume
314,840
Average volume
118,700
Market cap
29M+
52-week range
$1.87 – $6.93
50-day average
$4.27
200-day average
$3.60

Price action over the past year

In 252 trading sessions since November 17, 2025, GRDX closed higher on 115 days (46%). Its best day was December 30, 2025 (+23.28%) and its worst was November 13, 2026 (-31.00%). The stock moved 10% or more in a single session 53 times. It opened at least 5% above the previous day's high 2 times.

Recent signals

GRDX news

About GridAI Technologies Corp Com (New) 2025

Entero Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases. The Company is currently advancing a therapeutic development pipeline with multiple late-stage clinical programs built around its proprietary technologies, including: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for Celiac disease; capeserod, a selective 5-HT4 receptor partial agonist being developed for gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Similar stocks

Find more stocks like GRDX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.